Clinical Trial: NRG LU002

NRG LU002

Status: Closed

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

LU002 is permanently closed to accrual, effective December 6, 2023.